Key messages from scientific research that's ready to be acted on
Got It, Hide thisWoods B, Hawkins N, Mealing S, et al. Individual patient data network meta-analysis of mortality effects of implantable cardiac devices. Heart. 2015;101:1800-6.
In people with heart failure with reduced ejection fraction, are some cardiac devices implanted under the skin better than others for reducing risk of death?
Heart failure occurs when your heart can’t pump blood well enough to meet the needs of your body. Ejection fraction is a measure of how well your heart is pumping blood (over 50% is normal).
Devices can be implanted below the skin and connected to the heart to help it pump better and more regularly. Such devices include cardiac resynchronization therapy (CRT) pacemakers, implantable cardioverter defibrillators (ICDs), and combined devices (CRT pacemakers with defibrillation).
The researchers did a systematic review, searching for studies that were published in English up to June 2011.
They included 22 randomized controlled trials with13,350 people (average age 64 years, 77% men).
The key features of the studies were:
More work needs to be done to determine whether some people benefit more from some devices than others.
In people with heart failure and reduced ejection fraction, implantable cardiac devices with both resynchronization and defibrillation save more lives than resynchronization pacemakers or implantable defibrillators.
Treatment comparisons | Effect on deaths at an average of 2.5 years |
Combined device†vs medical therapy | Combined devices reduced deaths by about 42%‡ |
CRT pacemaker vs medical therapy | CRT pacemakers reduced deaths by about 28% |
ICD vs medical therapy | ICDs reduced deaths by about 29% |
Combined device†vs CRT pacemaker | Combined devices reduced deaths by about 19% |
Combined device†vs ICD | Combined devices reduced deaths by about 18% |
CRT = cardiac resynchronization therapy; ICD = implantable cardioverter defibrillator
*Trials were combined using a type of analysis that lets you compare treatments even if they were not compared directly in the individual trials.